

# 2014 Analysis of the US Hospital Tumor Marker Testing Market

<https://marketpublishers.com/r/2CC097597C7EN.html>

Date: November 2013

Pages: 567

Price: US\$ 5,200.00 (Single User License)

ID: 2CC097597C7EN

## Abstracts

This new report from Venture Planning Group contains 567 pages, 50 tables and presents a comprehensive analysis of the US hospital tumor market testing market, including:

Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next 5 years.

Mortality statistics and scientific views on the etiology of major types of cancer, e. g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.

Test volume and sales forecasts for 40 tumor markers performed in US hospitals.

Current instrumentation technologies and feature comparison of leading analyzers.

Sales and market shares of leading suppliers.

Emerging diagnostic technologies and their potential market applications.

Product development opportunities.

Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

Business opportunities and strategic recommendations for suppliers.

Contains 567 pages and 50 tables

## Contents

### INTRODUCTION

### WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

#### A. Cancer Statistics and Etiology

1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer

#### B. Major Current And Emerging Cancer Diagnostic Tests

1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27. 29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembryonic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)

- 20. Prostate-Specific Antigen (PSA)
- 21. Squamous Cell Carcinoma Antigen (SCC)
- 22. T and B Lymphocytes
- 23. TdT
- 24. Thyroglobulin
- 25. Tissue Polypeptide Antigen (TPA)
- 26. Biochemical Tumor Markers
  - ADA
  - B-Protein
  - PNP
  - 5'-Nucleotidase
- 27. Oncogenes
  - Abl/abl-bcr
  - AIB1
  - BCL-2
  - BRCA1
  - CD44
  - C-fos
  - C-myb
  - C-myc
  - CYP-17
  - Erb-B
  - HPC1
  - N-myc
  - P40
  - P51
  - P53
  - PIK3CA
  - PTI-1
  - Ras
  - Reg
  - Sis
  - Src
- 28. Polypeptide Growth Factors
  - Basic Fibroblast Growth Factor
  - Beta-TGF
  - Cachectin (TNT)
  - Calmodulin
  - ECFR

Nerve Growth Factor (NGF)  
Epidermal Growth Factor (EGF)  
Ornithine Decarboxylase  
Transferrin  
Transforming Growth Factor-Alpha  
29. Ectopic Hormones  
30. Colony Stimulating Factors  
31. Lymphokines  
Alpha-Interferon  
B Cell Growth Factors  
B Cell Growth Factor (BCGF)  
Gamma-Interferon  
Interleukin-1 (IL-1)  
Macrophage Activating Factor  
32. Immunohistochemical Stains  
33. Emerging Tumor Markers  
N-Acetylglucosamine  
Actin  
Alpha-Actin  
Antineuronal Antibodies  
7B2  
B72. 3  
Bax  
BCD-F9  
BLCA-4  
Blood Group Antigens A,B,H  
CA 50  
CA 72-4/TAG-72  
CA 195  
CA-242  
CA-549  
CAM 26  
CAR-3  
Cathepsin-D  
Chromogranin A and B  
Cluster 1 Antigen  
Cluster-5/5A Antigen  
CTA  
CU18

DR-70  
DU-PAN-2  
Endometrial Bleeding Associated Factor  
Endostatin  
Epithelial Membrane Antigen  
Feulgen Hydrolysis  
Fibronectin  
FSH  
(1->3)-L-fucosyltransferase  
Gastrin-Releasing Peptide (GRP)  
GDCFP-15  
Glucagon  
Glycoamines  
H23  
Her-2  
Human Carcinoma Antigen  
HPA  
HSP27  
Intermediate Filaments  
Cytokeratins/CK18/Cyfra 21-1  
Desmin  
Gliofibrillary Acid Protein  
Neurofilaments  
Vimentin  
KA 93  
Kinases  
KP16D3  
LAI  
Leukocyte Common Antigen  
Lewis Antigens  
Lysophosphatidic Acid (LPA)  
Ma 695/Ma 552  
MABDF3  
MAG  
ME1  
Minactivin  
MN/CA9  
MSA  
Mucin Cancer Antigen (MCA)

Multiple Tumor Suppressor 1  
Myosin  
NEA-130  
NMP22  
OA-519  
Opioid Peptides  
P-glycoprotein  
Pancreatic Oncofetal Antigen (POA)  
Placental Lactogen  
PR92  
Proliferative Index, Ki-67  
Px  
RB Inactivation/Deletion  
Ret  
SCCL 175  
Selectin  
Sialic Acid  
Sialyl SSEA-1/SLX  
SN10  
Somatostatin  
TA-90  
TABA  
Tachykinin  
TAG 12  
TPS  
Troponin  
Tubulin  
VCAM  
VEGF  
Villen

### C. Instrumentation Review And Market Needs

1. Abbott AxSYM
2. Abbott Architect c4000
3. Abbott Architect i2000 Series
4. Abbott Architect ci8200 System
5. Beckman Coulter UniCel Series
6. Beckman Coulter Access
7. Binding Site ESP600
8. bioMerieux Mini Vidas

9. Carolina Chemistries BioLis 24i
  10. DiaSorin Liaison
  11. Horiba ABX Pentra 400
  12. Inverness DS2
  13. J&J Vitros ECi/ECiQ
  14. J&J Vitros 3600
  15. J&J Vitros 5600
  16. Olympus AU5400
  17. Olympus AU3000i
  18. Olympus AU2700
  19. Roche Modular Analytics
  20. Roche Cobas Integra 400
  21. Roche Cobas Integra 400 Plus
  22. Roche Elecsys
  23. Roche Cobas c311
  24. Siemens ADVIA Centaur
  25. Siemens Dimension
  26. Siemens Dimension RxL Max
  27. Siemens Dimension Vista 500
  28. Siemens Immulite
  29. Siemens Stratus
  30. Tosoh AIA-Series
  31. Vital Diagnostics ATAC 8000
  32. Vital Diagnostics Envoy 500
- D. Current and Emerging Technologies
1. Monoclonal and Polyclonal Antibodies
  2. Immunoassays
    - a. Technological Principle
    - b. Radioimmunoassay (RIA)
    - c. Enzyme Immunoassays (EIA)
      - Overview
      - ELISA
      - Immunofiltration
      - Particle-Membrane Capture Immunoassay
      - Enzyme Amplification
    - d. Fluorescent Immunoassays
    - e. Luminescence
      - Chemiluminescence
      - Bioluminescence



- f. Latex Agglutination
- g. Immunoprecipitation
- h. Affinity Chromatographu
- e. Liposome Flow-Injection Immunoassay
- 3. Molecular Diagnostics a. Technology Overview
  - b. Amplification Methods
    - PCR
    - DAP-PCR
    - Immuno-PCR
    - QC-PCR
    - CAR
    - DNA
    - HPA
    - LCR
    - NASBA
    - QBR
    - SDA
    - 3 SR, and others
- 4. Chromosome Analysis
  - a. Chronic Myelogenous Leukemia (CML)
  - b. Acute Myeloid Leukemia (AML)
  - c. Acute Lymphoblastic Leukemia (ALL)
  - d. Malignant Lymphomas Lymphoid Malignancies
  - e. Chronic Lymphocytic Leukemia (CLL)
  - f. Solid Cancers
  - g. Chromosomal Translocation and Oncogenes
- 5. Artificial Intelligence
- 6. Flow Cytometry
- 7. Two Dimensional Gel Electrophoresis (2-DGE)
- 8. Biosensors
- 9. Competing/Complementing Technologies
  - a. CT
  - b. MRI
  - c. NMR
  - d. PET
  - e. Photonics Spectroscopy
- E. Personal Testing

**U.S.A.**

- A. Executive Summary
- B. Business Environment
  - 1. Health Care Expenditures
  - 2. Cost Consciousness
  - 3. Industry Consolidation
  - 4. Managed Care
  - 5. Hospitals
  - 6. Admissions
  - 7. Length of Stay
  - 8. Industry Diversification
  - 9. Physician Demographics
  - 10. Population Aging
    - a. Chronic Illness
    - b. Disease Incidence
    - c. Susceptibility to Iatrogenesis
    - d. Multiple Illness Cases
  - 11. Laboratory Regulations
- C. Market Structure
  - 1. Centralized Testing
    - a. Hospitals
    - b. Commercial/Private Laboratories
  - 2. POT/Decentralized Testing
    - a. Physician Offices/Group Practices
    - b. Cancer Clinics
    - c. Point-Of-Care Testing
    - d. Other Decentralized Testing Locations
- D. Market Size, Growth and Major Suppliers Sales, Instrument Placements and Market Shares

## **MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES**

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

## **DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS**

## **ALTERNATIVE MARKET PENETRATION STRATEGIES**

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
  - 1. Marketing Approaches
  - 2. Product Complexity
  - 3. Customer Preference
  - 4. Established Suppliers
  - 5. Emerging Suppliers
  - 6. Major Types of Distributors
  - 7. Market Segmentation Factor

## **POTENTIAL MARKET ENTRY BARRIERS AND RISKS**

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

## **COMPETITIVE PROFILES**

Abbott  
AdnaGen  
Applied Gene Technologies  
Arca  
Beckman Coulter/Danaher  
Becton Dickinson  
Biomedical Diagnostics bioMerieux  
Bio-Rad  
Cepheid  
Correlogic Systems  
Dako  
Decode  
Diadexus

Diagnocure  
Diasorin  
Eiken Chemical  
Enterix  
Enzo Biochem  
Epigenomics  
Exact Sciences  
Fujirebio  
Gen-Probe  
Guided Therapeutics  
Hologic  
Ipsogen  
Kreatech  
Kyowa Medex  
Life Technologies  
Mackay Life Sciences  
Myriad Genetics  
Nanogen Elitech  
OncoLab  
Otho-Clinical Diagnostics  
Panacea Pharmaceuticals  
Polartechnics  
Polymedco  
PreMD  
Qiagen  
Radient Pharmaceuticals  
Roche  
Scienion  
Sequenom  
Siemens Healthcare  
Takara Bio  
Targeted Diagnostics & Therapeutics  
Tosoh  
Veridex  
Wako Pure Chemicals  
Wallac/PE  
Zila

## List Of Tables

### LIST OF TABLES

Tumor Marker Classification Major Companies Developing or Marketing ACTH Tests  
Major Companies Developing or Marketing AFP Tests  
Major Companies Developing or Marketing Beta-2 Microglobulin Tests  
Major Companies Developing or Marketing CA 15-3/27. 29 Tests  
Major Companies Developing or Marketing CA 19-9 Tests  
Major Companies Developing or Marketing CA 125 Tests  
Major Companies Developing or Marketing Calcitonin Tests  
Major Companies Developing or Marketing CEA Tests  
Major Companies Developing or Marketing Estrogen Receptor Tests  
Major Companies Developing or Marketing Progesterone Receptor Tests  
Major Companies Developing or Marketing Ferritin Tests  
Major Companies Developing or Marketing Gastrin Tests  
Major Companies Developing or Marketing HCG Tests  
Major Companies Developing or Marketing Insulin Tests  
Major Companies Developing or Marketing NSE Tests  
Major Companies Developing or Marketing Occult Blood Tests  
Major Companies Developing or Marketing PAP Smear/HPV Tests  
Major Companies Developing or Marketing PAP Tests  
Major Companies Developing or Marketing PSA Tests  
Major Companies Developing or Marketing Lymphocyte Subclassification Tests  
Biochemical Markers Potential Applications In Cancer  
Diagnosis Oncogenes Potential Applications In Cancer  
Diagnosis Major Companies Developing or Marketing Oncogene Tests  
Growth Factors Potential Applications In Cancer  
Diagnosis Colony Stimulating Factors Potential Applications in Cancer  
Diagnosis Lymphokines Potential Applications In Cancer  
Diagnosis Immunohistochemical Stains Potential Applications in Cancer  
Executive Summary Table: U.S., Hospital Cancer Diagnostic Test Volume and Sales Forecast  
U.S., Estimated New Cancer Cases and Deaths  
U.S., Estimated Cancer Death Rates Per 100,000 Population  
U.S., Laboratories Performing Cancer Diagnostic Tests  
U.S., Hospital Laboratories Performing Cancer Diagnostics Tests by Bed Size  
U.S., Hospital Laboratories Major Cancer Diagnostic Test Volume Forecast by Test  
U.S., Total Cancer Diagnostics Sales By Major Supplier

U.S., ACTH Testing Market Diagnostics Sales by Major Supplier  
U.S., AFP Testing Market Diagnostics Sales by Major Supplier  
U.S., Beta-2 Migroblolulin Testing Market Diagnostics Sales by Major Supplier  
U.S., CA 15-3/27. 29 Testing Market Diagnostics Sales by Major Supplier  
U.S., CA 19-9 Testing Market Diagnostics Sales by Major Supplier  
U.S., CA 125 Testing Market Diagnostics Sales by Major Supplier  
U.S., CEA Testing Market Diagnostics Sales by Major Supplier  
U.S., Ferritin Testing Market Diagnostics Sales by Major Supplier  
U.S., HCG Testing Market Diagnostics Sales by Major Supplier  
U.S., Insulin Testing Market Diagnostics Sales by Major Supplier  
U.S., Parathyroid Hormone Testing Market Diagnostics Sales by Major Supplier  
U.S., PAP Testing Market Diagnostics Sales by Major Supplier  
U.S., Progesterone Receptor Testing Market Diagnostics Sales by Major Supplier  
U.S., PSA Testing Market Diagnostics Sales by Major Supplier

## I would like to order

Product name: 2014 Analysis of the US Hospital Tumor Marker Testing Market

Product link: <https://marketpublishers.com/r/2CC097597C7EN.html>

Price: US\$ 5,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2CC097597C7EN.html>